✦ LIBER ✦

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

✍ Scribed by Jun Zhu, Te Li, Xiaohui Wang, Ming Ye, Jian Cai, Yuejuan Xu, Bin Wu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN110 Economic Evaluation of Gefitinib

✍ Fragoulakis, V.; Pallis, A.; Kourlaba, G.; Georgoulias, V.; Maniadakis, N. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PCN75 COST-EFFECTIVENESS ANALYSIS OF EGF

✍ O Arrieta; P Anaya; RJ López; AC Polanco 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Combination of EGFR gene copy number and

✍ Hirsch, F.; Varella-Garcia, M; Cappuzzo, F; McCoy, J; Bemis, L; Xavier, A.; Dzia 📂 Article 📅 2007 🏛 Oxford University Press 🌐 English ⚖ 127 KB

26 Audit of gefitinib for the first-line

✍ Douglas, R.; Campbell, L.; McAleese, J.; Scullin, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Prospective Phase II Study of Gefitinib

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB

Erlotinib versus chemotherapy as first-l

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB